Fluidigm Corporation (NASDAQ: FLDM) is one of 18 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its competitors? We will compare Fluidigm Corporation to similar companies based on the strength of its dividends, institutional ownership, profitability, valuation, risk, analyst recommendations and earnings.
This is a breakdown of recent ratings and price targets for Fluidigm Corporation and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fluidigm Corporation Competitors||113||479||788||16||2.51|
Fluidigm Corporation presently has a consensus target price of $9.00, suggesting a potential upside of 73.41%. As a group, “Medical Software & Technology Services” companies have a potential upside of 16.67%. Given Fluidigm Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Fluidigm Corporation is more favorable than its competitors.
This table compares Fluidigm Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fluidigm Corporation Competitors||-18.37%||-12.09%||-2.31%|
Risk and Volatility
Fluidigm Corporation has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Fluidigm Corporation’s competitors have a beta of 1.33, indicating that their average share price is 33% more volatile than the S&P 500.
Institutional and Insider Ownership
88.9% of Fluidigm Corporation shares are held by institutional investors. Comparatively, 63.1% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 4.7% of Fluidigm Corporation shares are held by insiders. Comparatively, 21.9% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Fluidigm Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Fluidigm Corporation||$96.72 million||-$62.62 million||-2.11|
|Fluidigm Corporation Competitors||$376.15 million||$34.64 million||9.21|
Fluidigm Corporation’s competitors have higher revenue and earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Fluidigm Corporation competitors beat Fluidigm Corporation on 7 of the 12 factors compared.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.